Dear Editor, Nivolumab is a fully human monoclonal antibody that targets the programmed cell death 1 (PD-1) immune checkpoint.
Publications
FDA Grants Fast Track Designation to Nemvaleukin Alfa for Mucosal Melanoma
Nemvaleukin alfa (Nemvaleukin) has been granted fast-track designation by the FDA for the treatment of patients with mucosal melanoma who have received prior treatment with an anti–PD-L1 therapy, according to a press release from Alkermes.1
FDA Sets PDUFA Date for Pembrolizumab
Merck announced that its phase 3 KEYNOTE-716 (NCT03553836) trial investigating pembrolizumab (Keytruda) has met its primary endpoint…
Clinical characteristics and prognosis of acral lentiginous melanoma: A single-center series of 211 cases in China
Researchers conducted this retrospective observational study to summarize and analyze the clinical features, treatment strategy, treatment effect, and prognostic factors of acral lentiginous melanoma (ALM) in a Chinese population.